{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-016709","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.773132+00:00","generated_at":"2026-05-26T04:50:35.274222+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicycle Therapeutics reports Q4/FY24 net loss $169M; cash $879.5M; zelenectide pevedotin shows 65% ORR in mUC","bullets":["Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.","Net loss $169.0M ($2.90 per share) for FY2024 vs $180.7M ($5.08 per share) in FY2023.","Phase 1 Duravelo-1: 65% ORR (13/20) for zelenectide pevedotin + pembrolizumab in first-line mUC; no Grade 4/5 TRAEs of interest.","FDA Fast Track granted for zelenectide pevedotin in NECTIN4-amplified TNBC and NSCLC; new Phase 1/2 trials planned in 2025.","R&D expenses $173.0M in FY2024, up from $156.5M in FY2023, driven by zelenectide pevedotin development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-016709","json":"https://secwatch.observer/filing/0001104659-25-016709.json","markdown":"https://secwatch.observer/filing/0001104659-25-016709.md","text":"https://secwatch.observer/filing/0001104659-25-016709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925016709/0001104659-25-016709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925016709/tm257327d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:50:35.274222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}